Compare · IGMS vs NVO
IGMS vs NVO
Side-by-side comparison of IGM Biosciences Inc. (IGMS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IGMS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $220.35B, about 393.3x IGMS ($560.3M).
- NVO has hit the wire 5 times in the past 4 weeks while IGMS has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 24 for IGMS).
- Company
- IGM Biosciences Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $560.3M
- $220.35B
- 1M return
- -5.90%
- -
- 1Y return
- +0.00%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 0
- 5
- Recent ratings
- 24
- 25
IGM Biosciences Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IGMS
- SEC Form 15-12G filed by IGM Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by IGM Biosciences Inc.
- SEC Form 4 filed by Former 10% owner and director Baker Bros. Advisors Lp
- Amendment: SEC Form SCHEDULE 13D/A filed by IGM Biosciences Inc.
- Director Redmile Group, Llc returned 2,964,843 shares to the company (SEC Form 4)
- SEC Form EFFECT filed by IGM Biosciences Inc.
- SEC Form EFFECT filed by IGM Biosciences Inc.
- SEC Form EFFECT filed by IGM Biosciences Inc.
- SEC Form EFFECT filed by IGM Biosciences Inc.
- SEC Form EFFECT filed by IGM Biosciences Inc.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S